Date:11/12/2010

s, plans and objectives of management are forward-looking statements.  The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete response letter regarding our new drug application for Linjeta™ in a timely manner and the possibility that information we provide in response to the letter may not be accepted by the FDA; our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the FDA's findings regarding data anomalies observed in India in our Phase 3 clinical trial of Linjeta™ for patients with Type 1 diabetes; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our
'/>"/>

SOURCE Biodel Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
2. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
3. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta™
4. Biodel to Present at Upcoming Conferences
5. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
6. Biodel Appoints Arthur Urciuoli to its Board of Directors
7. Biodel to Raise $9.4 Million Through Registered Direct Offering
8. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
9. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
10. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
11. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe